Loading…

Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment

Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are po...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmacology 2009-10, Vol.76 (4), p.710-722
Main Authors: Huang, Xi-Ping, Setola, Vincent, Yadav, Prem N., Allen, John A., Rogan, Sarah C., Hanson, Bonnie J., Revankar, Chetana, Robers, Matt, Doucette, Chris, Roth, Bryan L.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 722
container_issue 4
container_start_page 710
container_title Molecular pharmacology
container_volume 76
creator Huang, Xi-Ping
Setola, Vincent
Yadav, Prem N.
Allen, John A.
Rogan, Sarah C.
Hanson, Bonnie J.
Revankar, Chetana
Robers, Matt
Doucette, Chris
Roth, Bryan L.
description Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then “functionally profiled” (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC50 data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.
doi_str_mv 10.1124/mol.109.058057
format article
fullrecord <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2769050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0026895X2402039X</els_id><sourcerecordid>S0026895X2402039X</sourcerecordid><originalsourceid>FETCH-LOGICAL-e204t-120d2d39beedf8ab1456eadf44b4623c9a40bb04f72262a8aefc619c2725a8463</originalsourceid><addsrcrecordid>eNpVUcuO1DAQtBCIHRaunH3hmMH2OC8OSGFh2ZVWYsRL3KyO00mMnDiyPYF8Cz-LR8OFU5fU1VWqLkJecrbnXMjXk7N7zuo9yyuWl4_IjueCZ4xz_pjsGBNFVtX5jyvyLISfjHGZaE_JFa_zktUy35E_R_BgLVp6e5p1NG4GS5sEVhM3evSuN9bMA_2MK4IN9DvY9WTdAnF0A86BNh7p0UWcI82zu63z7vcW_bZEmMyM4l261LhE52kzuNmEGN7Q-2mxRsPZLdA-rd7700C_QI_JswkBQ5iS4HPypE-e-OLfvCbfbj98vbnLHj59vL9pHjIUTMaMC9aJ7lC3iF1fQZtCFghdL2UrC3HQNUjWtkz2pRCFgAqw1wWvtShFDpUsDtfk7UV3ObUTdjpZp5-oxZsJ_KYcGPX_ZjajGtyqRFnULGdJ4NVFYDTD-Mt4VMsIfgLtrBs2VRZKqpKfedWFhynNatCroA3OGrt0o6PqnFGcqXOxKhWbcK0uxR7-AgYim4k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment</title><source>Free Full-Text Journals in Chemistry</source><creator>Huang, Xi-Ping ; Setola, Vincent ; Yadav, Prem N. ; Allen, John A. ; Rogan, Sarah C. ; Hanson, Bonnie J. ; Revankar, Chetana ; Robers, Matt ; Doucette, Chris ; Roth, Bryan L.</creator><creatorcontrib>Huang, Xi-Ping ; Setola, Vincent ; Yadav, Prem N. ; Allen, John A. ; Rogan, Sarah C. ; Hanson, Bonnie J. ; Revankar, Chetana ; Robers, Matt ; Doucette, Chris ; Roth, Bryan L.</creatorcontrib><description>Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then “functionally profiled” (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC50 data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.</description><identifier>ISSN: 0026-895X</identifier><identifier>EISSN: 1521-0111</identifier><identifier>DOI: 10.1124/mol.109.058057</identifier><identifier>PMID: 19570945</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Molecular pharmacology, 2009-10, Vol.76 (4), p.710-722</ispartof><rights>2009 American Society for Pharmacology and Experimental Therapeutics</rights><rights>2009 The American Society for Pharmacology and Experimental Therapeutics</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Huang, Xi-Ping</creatorcontrib><creatorcontrib>Setola, Vincent</creatorcontrib><creatorcontrib>Yadav, Prem N.</creatorcontrib><creatorcontrib>Allen, John A.</creatorcontrib><creatorcontrib>Rogan, Sarah C.</creatorcontrib><creatorcontrib>Hanson, Bonnie J.</creatorcontrib><creatorcontrib>Revankar, Chetana</creatorcontrib><creatorcontrib>Robers, Matt</creatorcontrib><creatorcontrib>Doucette, Chris</creatorcontrib><creatorcontrib>Roth, Bryan L.</creatorcontrib><title>Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment</title><title>Molecular pharmacology</title><description>Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then “functionally profiled” (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC50 data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.</description><issn>0026-895X</issn><issn>1521-0111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNpVUcuO1DAQtBCIHRaunH3hmMH2OC8OSGFh2ZVWYsRL3KyO00mMnDiyPYF8Cz-LR8OFU5fU1VWqLkJecrbnXMjXk7N7zuo9yyuWl4_IjueCZ4xz_pjsGBNFVtX5jyvyLISfjHGZaE_JFa_zktUy35E_R_BgLVp6e5p1NG4GS5sEVhM3evSuN9bMA_2MK4IN9DvY9WTdAnF0A86BNh7p0UWcI82zu63z7vcW_bZEmMyM4l261LhE52kzuNmEGN7Q-2mxRsPZLdA-rd7700C_QI_JswkBQ5iS4HPypE-e-OLfvCbfbj98vbnLHj59vL9pHjIUTMaMC9aJ7lC3iF1fQZtCFghdL2UrC3HQNUjWtkz2pRCFgAqw1wWvtShFDpUsDtfk7UV3ObUTdjpZp5-oxZsJ_KYcGPX_ZjajGtyqRFnULGdJ4NVFYDTD-Mt4VMsIfgLtrBs2VRZKqpKfedWFhynNatCroA3OGrt0o6PqnFGcqXOxKhWbcK0uxR7-AgYim4k</recordid><startdate>200910</startdate><enddate>200910</enddate><creator>Huang, Xi-Ping</creator><creator>Setola, Vincent</creator><creator>Yadav, Prem N.</creator><creator>Allen, John A.</creator><creator>Rogan, Sarah C.</creator><creator>Hanson, Bonnie J.</creator><creator>Revankar, Chetana</creator><creator>Robers, Matt</creator><creator>Doucette, Chris</creator><creator>Roth, Bryan L.</creator><general>Elsevier Inc</general><general>American Society for Pharmacology and Experimental Therapeutics</general><general>The American Society for Pharmacology and Experimental Therapeutics</general><scope>5PM</scope></search><sort><creationdate>200910</creationdate><title>Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment</title><author>Huang, Xi-Ping ; Setola, Vincent ; Yadav, Prem N. ; Allen, John A. ; Rogan, Sarah C. ; Hanson, Bonnie J. ; Revankar, Chetana ; Robers, Matt ; Doucette, Chris ; Roth, Bryan L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e204t-120d2d39beedf8ab1456eadf44b4623c9a40bb04f72262a8aefc619c2725a8463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Xi-Ping</creatorcontrib><creatorcontrib>Setola, Vincent</creatorcontrib><creatorcontrib>Yadav, Prem N.</creatorcontrib><creatorcontrib>Allen, John A.</creatorcontrib><creatorcontrib>Rogan, Sarah C.</creatorcontrib><creatorcontrib>Hanson, Bonnie J.</creatorcontrib><creatorcontrib>Revankar, Chetana</creatorcontrib><creatorcontrib>Robers, Matt</creatorcontrib><creatorcontrib>Doucette, Chris</creatorcontrib><creatorcontrib>Roth, Bryan L.</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Xi-Ping</au><au>Setola, Vincent</au><au>Yadav, Prem N.</au><au>Allen, John A.</au><au>Rogan, Sarah C.</au><au>Hanson, Bonnie J.</au><au>Revankar, Chetana</au><au>Robers, Matt</au><au>Doucette, Chris</au><au>Roth, Bryan L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment</atitle><jtitle>Molecular pharmacology</jtitle><date>2009-10</date><risdate>2009</risdate><volume>76</volume><issue>4</issue><spage>710</spage><epage>722</epage><pages>710-722</pages><issn>0026-895X</issn><eissn>1521-0111</eissn><abstract>Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then “functionally profiled” (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC50 data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.</abstract><pub>Elsevier Inc</pub><pmid>19570945</pmid><doi>10.1124/mol.109.058057</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0026-895X
ispartof Molecular pharmacology, 2009-10, Vol.76 (4), p.710-722
issn 0026-895X
1521-0111
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2769050
source Free Full-Text Journals in Chemistry
title Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A26%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Parallel%20Functional%20Activity%20Profiling%20Reveals%20Valvulopathogens%20Are%20Potent%205-Hydroxytryptamine2B%20Receptor%20Agonists:%20Implications%20for%20Drug%20Safety%20Assessment&rft.jtitle=Molecular%20pharmacology&rft.au=Huang,%20Xi-Ping&rft.date=2009-10&rft.volume=76&rft.issue=4&rft.spage=710&rft.epage=722&rft.pages=710-722&rft.issn=0026-895X&rft.eissn=1521-0111&rft_id=info:doi/10.1124/mol.109.058057&rft_dat=%3Celsevier_pubme%3ES0026895X2402039X%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e204t-120d2d39beedf8ab1456eadf44b4623c9a40bb04f72262a8aefc619c2725a8463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19570945&rfr_iscdi=true